Physician profile
David Munyan
NPI 1336862721
$1,006.81
in general payments reported to CMS, 2019-2025
13 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $583 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $189.78 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $173.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $122.20 | 2025 | Austedo Xr |
| Lilly USA, LLC | $110.50 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $77.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $76.91 | 2024-2025 | |
| Coloplast Corp | $75.21 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.23 | 2025 | Ofev |
| Pfizer INC. | $34.80 | 2024 | |
| Dexcom, INC. | $24.04 | 2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $22.30 | 2024 | Crysvita |
| Amgen INC. | $22.05 | 2024 | Tavneos |
| Alexion Pharmaceuticals, INC. | $21.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Munyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.